Manchester-based Boston Therapeutics wins approval for blood glucose moderating supplement trials in France

Manchester, N.H.-based Boston Therapeutics Inc. (OTCQB: BTHE) announced today that France’s Ministry of Health and the East IV Committee of Protection of Persons (Strasbourg) has approved the pharmaceutical company’s blood glucose-moderating dietary supplement for clinical study to test its efficacy and safety for Type II diabetes patients.


To improve the chance of seeing your comment posted here or published in the New Hampshire Union Leader:

  • Identify yourself. Accounts using fake or incomplete names are suspended regardless of the quality of posts.
  • Say something new, stay on topic, keep it short.
  • Links to outside URLs are discouraged, if used they should be on topic.
  • Avoid comments in bad taste, write well, avoid using all capital letters
  • Don't cite facts about individuals or businesses without providing a means to verify the claim
  • If you see an objectionable comment please click the "Report Abuse" button and be sure to tell us why.

Note: Comments are the opinion of the respective poster and not of the publisher.

Be the first to comment.

Post a comment

You must sign in before you can post comments. If you are experiencing issues with your account please e-mail